CTLA4 and hypophysitis: When compared to PD-1 and PD-L1 inhibitors, CTLA4 inhibitors are more likely to cause colitis, hypophysitis, and dermatitis, while pneumonitis, hypothyroidism, and skeletal symptoms (myalgias, arthralgias) are less frequent [26].